MUC5B: A Good Target for Future Therapy in Pulmonary Fibrosis?

Thorax - United Kingdom
doi 10.1136/thoraxjnl-2012-202957
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Micro RNAs: The Future of Idiopathic Pulmonary Fibrosis Therapy

Cell Biochemistry and Biophysics
MedicineBiochemistryCell BiologyBiophysics
2014English

Triple Therapy for Idiopathic Pulmonary Fibrosis

Thorax
PulmonaryRespiratory Medicine
2012English

Current and Future Therapies for Idiopathic Pulmonary Fibrosis

Pulmonary Therapy
2015English

Cell Therapy in Idiopathic Pulmonary Fibrosis†

Medical Sciences
2018English

Reply: Rationale for Anticoagulant Therapy of Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2014English

Pharmacologic Therapies for Idiopathic Pulmonary Fibrosis, Past and Future

Annals of Medicine
Medicine
2015English

Pathogenesis, Current Treatments and Future Directions for Idiopathic Pulmonary Fibrosis

Current Opinion in Pharmacology
Drug DiscoveryPharmacology
2013English

FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2015English

Idiopathic Pulmonary Fibrosis: Current Challenges and Future Perspectives

European Respiratory Review
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy